Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Matthew Wheeler, MD, PhD
Healthcare Professional Assistant Professor
Stanford University Medical Center
300 Pasteur Drive
2nd Floor, Room A260
Stanford, California, United States
Matthew Wheeler is an Assistant Professor of Medicine (Cardiovascular Medicine) at the Stanford University Medical Center. He is also an Adult Medical Director and Executive Director at Stanford Center of Undiagnosed Diseases. He graduated from University of Chicago Pritzker School of Medicine and has been in practice for 12 years. He completed his residency at Stanford University. He specializes in Internal Medicine.
He is physician scientist with interests in cardiomyopathies, rare and undiagnosed diseases, therapeutics and genomics. He is a physician with interest and experience treating patients with hypertrophic cardiomyopathy and other inherited cardiomyopathies. Dr. Wheeler has made extensive translational science efforts, participating in several ongoing clinical trials for hypertrophic cardiomyopathy, dilated cardiomyopathy, ATTR cardiac amyloidosis, and mechanical circulatory support.
Dr. Wheeler is a co-investigator of the Bioinformatics Center of the Molecular Transducers of Physical Activity Consortium. He pursue projects and collaborations at the intersection of striated muscle genetics, genomics, and clinical investigation.
Representative Publications:
myBinderRelated Content
-
Todd Michael Koelling, MDTodd Michael Koelling joined the Univers...
-
Treatment for ATTR Cardiomyopathy – ASG Webinar 2/7https://www.youtube.com/watch?v=IzC_yaqs...
-
Jignesh K. Patel, MD, PhDJignesh K. Patel is a Cardiologist at Ce...
-
Amit R. Patel, MDDr. Amit R. Patel is Professor at UVA He...
-
Pathophysiology and Treatment of Cardiac AmyloidosisAmyloid cardiomyopathy should be suspect...
-
Martha Grogan, MDMartha Grogan is a Cardiologist-Internis...
-
U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare a...Pfizer Inc. announced today that the U.S...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
